Hormonal
GLP-1 receptor agonists (GLP1-RAs) and dual GIP/GLP1-RAs (e.g., tirzepatide) significantly reduce body fat distribution (visceral, subcutaneous, epicardial) and anthropometric indices (BMI, waist circumference) in overweight or obese adults with or without type 2 diabetes.
If you are overweight or obese, especially with type 2 diabetes, GLP-1 receptor agonists are a proven pharmacological option to reduce body fat, including dangerous visceral fat, and improve metabolic health. These medications work by targeting hormones that regulate appetite and satiety. Consult a doctor to see if an injectable medication like semaglutide or tirzepatide is appropriate for your specific health profile and goals.
existing clinical trials and previous systematic reviews also illustrated that GLP1-RAs have further benefits on change in body composition and anthropometric indices (i.e., visceral, subcutaneous, epicardial fat mass, BMI, and waist circumference)
Why this rating
This is a protocol for a systematic review; no primary data or pooled results are presented yet.
Source
Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials
Nuttaya Wachiraphansakul et al. · PLoS ONE · 2024
DOI 10.1371/journal.pone.0297488
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →